3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Lymphoma
34
Leukemia
34
Lymphoma, Follicular
27
Melanoma
25
Leukemia, Lymphocytic, Chronic, B-Cell
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Lymphoma, Non-Hodgkin
20
Leukemia, Myeloid, Acute
20
Multiple Myeloma
18
Breast Neoplasms
18
Lymphoma, Large B-Cell, Diffuse
17
Prostatic Neoplasms
15
Lymphoma, Mantle-Cell
15
Lymphoma, Large-Cell, Immunoblastic
15
Neuroblastoma
14
Neoplasms, Plasma Cell
13
Myelodysplastic Syndromes
13
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
13
Hodgkin Disease
13
Burkitt Lymphoma
13
Leukemia, Myeloid, Chronic-Phase
12
Neoplasm Metastasis
11
Lymphoma, B-Cell, Marginal Zone
11
Lung Neoplasms
10
Glioblastoma
9
Carcinoma, Non-Small-Cell Lung
9
Myeloproliferative Disorders
8
Leukemia, Myeloid, Accelerated Phase
8
Ovarian Neoplasms
7
Gliosarcoma
7
Interventions
apatinib
3
vistusertib
2
olaparib
2
camrelizumab
2
atezolizumab
2
Ipilimumab
2
Everolimus
2
trametinib
1
toripalimab
1
tilsotolimod
1
tazemetostat
1
tazarotene
1
spartalizumab
1
seviteronel
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
roniciclib
1
romiplostim
1
pyrotinib
1
phosphorylethanolamine
1
pemigatinib
1
pembrolizumab
1
pazopanib
1
palbociclib
1
niraparib
1
magrolimab
1
lenvatinib
1
irinotecan sucrosofate
1
famitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Solid Tumor
×
sargramostim
×
Clear all
NCT05284214
2023-09-15
SALIENT
Partner Therapeutics, Inc.
Phase 2
Withdrawn